Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. -- The children of females revealed during having a baby to a part of Vivus' weight-loss pharmaceutical Qnexa had better pay of dental beginning problems when in comparison to children not revealed to the pharmaceutical during having a baby, according to meantime research outcomes published Thursday evening. Vivus stocks dropped $1, or 9.6% to $9.40 in after-hours trading Thursday. The drop in Vivus' stock price shows individual concerns that the greater amount of beginning problems discovered with the Qnexa element may endanger the organization's initiatives at getting the weight-loss pharmaceutical accepted next year. Chris Tam, Vivus' chief executive, said in a report that the prevalance of beginning problems recognized from Wednesday's research were in line with in the past revealed studies and that the organization was discussing the new data with the U.S. Food and Drug Administration. Vivus, in its Thursday evening report, was careful not to attract any results from the beginning flaw research and didn't say whether the outcomes made Qnexa's acceptance any more or less likely. The organization isn't positioning an individual business call.Canada Goose Chilliwack BomberWomen in the first trimester of having a baby who took the epilepsy pharmaceutical topirimate, one of two substances that make up Vivus' Qnexa, were at a two-fold chance of labor to a kid with a cleft lip or taste when in comparison to females who also took topirimate in the past but not during having a baby. The real amount of dental beginning flaw in females who took topirimate during having a baby was 0.29% when in comparison to 0.16% in females with prior experience the pharmaceutical. In another research, expectant mothers who took topirimate during the first trimester were five times more likely to give beginning to a kid with an dental beginning flaw when in comparison to a management number of expectant mothers not revealed to topirimate. Here, the real amount of cleft mouth and taste was 0.36% compared to 0.07%, although Vivus said the amount of beginning problems in the management number of females may be synthetically low due to unique problem. U.S. specialists have in the past published safety safety measures about the chance of cleft mouth and palates in children created to females who took topirimate during having a baby.